Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics (NASDAQ:HRTX) in a research report sent to investors on Friday, January 5th. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on HRTX. ValuEngine upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Sunday, December 31st. Leerink Swann began coverage on Heron Therapeutics in a research report on Tuesday, January 2nd. They set an outperform rating and a $22.00 price objective for the company. BidaskClub upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Wednesday, December 20th. Zacks Investment Research upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Wednesday, November 8th. Finally, Noble Financial restated a buy rating and issued a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Heron Therapeutics currently has an average rating of Buy and a consensus price target of $28.82.

Heron Therapeutics (HRTX) traded down $0.40 on Friday, reaching $23.90. The company’s stock had a trading volume of 947,181 shares, compared to its average volume of 1,110,000. The firm has a market capitalization of $1,300.00, a P/E ratio of -6.31 and a beta of 2.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 12-month low of $12.25 and a 12-month high of $24.80.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. research analysts predict that Heron Therapeutics will post -3.37 earnings per share for the current fiscal year.

In other news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 19.93% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. Janus Henderson Group PLC acquired a new position in shares of Heron Therapeutics in the second quarter worth $78,134,000. Perceptive Advisors LLC acquired a new position in shares of Heron Therapeutics in the third quarter worth $5,329,000. Vanguard Group Inc. increased its position in Heron Therapeutics by 11.8% during the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock worth $29,036,000 after buying an additional 221,362 shares during the last quarter. Rubric Capital Management LP increased its position in Heron Therapeutics by 11.8% during the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after buying an additional 200,000 shares during the last quarter. Finally, Chartwell Investment Partners LLC acquired a new position in Heron Therapeutics during the third quarter worth $2,340,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.mareainformativa.com/2018/01/29/heron-therapeutics-hrtx-pt-set-at-31-00-by-cantor-fitzgerald-updated-updated-updated.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.